Sentences with phrase «in median survival»

Encouragingly, this anti-tumor effect converted into a pro-survival effect also, as the authors noted an improvement in the median survival of mice treated with the long - term expanded iPSC - NKs or PB - NKs from 73 days to 98 and 97 days, respectively (See adjoined figure).

«We report much higher therapeutic efficacy in preclinical brain tumor models using the combination of both therapies, leading to an increase in median survival,» Lowenstein says.

Brahmer emphasizes that the relatively small increase in median survival time with the use of the new immunotherapy drugs may be somewhat misleading in terms of overall impact of the medicines.

Furthermore, the onset of death in the 240 CAG mice was delayed by 3 - 4 weeks, but once initiated the progression was faster than that observed in the 110 CAG mice and resulted in median survivals that differed by 1.5 weeks.

Not exact matches

MicroMentor reports that participating businesses had a 75 percent increase in median annual business sales and an 87 percent survival rate year over year.

More specifically, their median survival is 9.6 years (compared to 6.4 years for the mouse lemurs in the control group).

«Patients who respond to immunotherapy tend to continue their responses for long durations, and these lengthier responses are cut off in calculations of median overall survival,» she says.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

A follow - up of the 48 patients who were evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.

Of the dogs stricken with osteosarcoma, 35 had the cancer in a leg which was subsequently amputated, followed by chemotherapy, which is the standard - of - care treatment; the dogs with elevated total cholesterol had a median survival time of 455 days, more than 200 days greater than the median survival time for dogs with normal cholesterol.

In examining the STS - CMS linked data, researchers found that the median survival following lung cancer surgery for pathologic Stage I (early stage) was 6.7 years, almost 2 years longer than the benchmark 5 - year survival rate.

At a median follow - up of 2.74 years, the median recurrence - free survival was 26.1 months (95 % confidence interval (CI) 19.3 — 39.3) in the Ipilimumab group and 17.1 months (95 % CI 13.4 — 21.6) in the placebo group (hazard ratio 0.75; 95 % CI 0.64 — 0.90; p = 0.0013).

Median progression - free survival for the 13 patients who had a decrease in the number of CTCs with ALK copy number gain was 14.0 months, while the median progression - free survival for the 16 patients who had stable or increased numbers of CTCs with ALK copy number gain was 6.1 mMedian progression - free survival for the 13 patients who had a decrease in the number of CTCs with ALK copy number gain was 14.0 months, while the median progression - free survival for the 16 patients who had stable or increased numbers of CTCs with ALK copy number gain was 6.1 mmedian progression - free survival for the 16 patients who had stable or increased numbers of CTCs with ALK copy number gain was 6.1 months.

As reported in 2015, the study met its primary endpoint after a median follow up of 2.3 years, with ipilimumab significantly improving recurrence - free survival.2 The drug was subsequently approved by the US Food and Drug Administration as adjuvant therapy for stage III melanoma.

«In the course of the disease progression, cirrhosis may lead to HCC, the prognosis for which is extremely poor — the median length of survival is approximately 12 - 15 months.

In patients with HLA - A2 and methylated MGMT, neither the control group nor the treatment group has reached a median survival point to date.

Median progression - free survival, which increased by three months in patients receiving therapy, was statistically significant.

Median progression - free survival improved by 4.5 months, from about six months in the control group to about 10.5 months among those treated.

In the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocoIn the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocoin patients treated according to protocol.

BRAF inhibitors prolonged median survival in clinical trials by about seven months.

But for the hundred or so cougars living in the rugged Santa Cruz mountains, the four - lane thoroughfare, divided in places by tall medians, is a formidable barrier that threatens their long - term survival.

There was no statistically significant difference in median overall survival.

Despite recent advances in understanding this disease, the median survival of glioblastoma patients is only 15 months, and survival statistics have not significantly improved over the past three decades.

The team found that patients with more varied types of bacteria in their digestive tract had longer median progression - free survival, defined at the time point where half of studied patients have their disease progress.

The researchers then tested their scoring method using data on 688 AML patients in three different clinical trials, In each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scorein three different clinical trials, In each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scoreIn each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scores.

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow - up show that 5 - FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)- radiotherapy for patients with cT3 - resectable T4 M0 rectal cancer does not improve survival or disease - free survival.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

The researchers found that patients capable of holding their breath over the course of treatment had a 90 percent disease - free survival, and a 96 percent overall survival, with a median reduction in radiation dose to the heart of 62 percent.

Based on recent information on the mechanisms of chemotherapy, a team of researchers of the McGill University Health Centre (MUHC) developed a new clinical approach to increase the efficiency of treatment in glioblastomas that increased the median survival to 22 months — bringing much needed hope to those affected by this aggressive disease.

Those that got Photofrin either intravenously or encapsulated in nanoparticles had a median survival time of 13 days.

Median progression - free survival with niraparib compared to placebo was 21.0 vs 5.5 months in the germline BRCA mutation group (hazard ratio [HR] 0.27, 95 % confidence interval [CI] 0.173 to 0.410, p < 0.0001), 9.3 months vs 3.9 months in the non-germline BRCA mutation group (HR 0.45, 95 % CI 0.338 to 0.607, p < 0.0001), and 12.9 vs 3.8 months in a subgroup of the non-mutation cohort who had homologous recombination DNA repair deficiencies (HRD)(HR 0.38, 95 % CI 0.243 to 0.586, p < 0.0001).

The median progression - free survival in these patients was 10 months.

The median disease - free survival was 13.4 months in the treatment group compared with 6.7 months in the observation group.

The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.

The median survival age was 49.7 years in 2012, up from 31.9 years in 1990, Dr. Anne Stephenson, a respirologist and research at St. Michael's Hospital wrote in the European Respiratory Journal.

In Canada, one in every 3,600 children are diagnosed with CF.. But life expectancy rates have risen dramatically in recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplantIn Canada, one in every 3,600 children are diagnosed with CF.. But life expectancy rates have risen dramatically in recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplantin every 3,600 children are diagnosed with CF.. But life expectancy rates have risen dramatically in recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplantin recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplants.

Among 128 of the 141 patients, the scientists found that the median progression - free survival of 71 patients identified with high levels of cancer DNA in their blood was 2.1 months, compared with 5.8 months for 57 patients with low levels.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Sweeney said more time is needed to assess the benefit of the drug combination in the men with lesser burdens of disease, as their median survival has not yet been reached.

The tumors grew rapidly in the control experiments (the median time for tumor - free survival was one week) and any differences in tumor - free survival for the controls and the mice injected with cells expressing mutated PREX2 were not statistically significant (Horrigan et al., 2017).

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 monthIn the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 monthin the ADT - only group — a difference of 17 months.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

Those with mutations had a median overall survival of 19.1 months, compared with 9.3 months in those with EGFR mutations.

The data reported today show continued increases in median event - free survival and muscle function scores as well as achievement of developmental milestones.

With a median follow up of 22 months, the 2 - year overall survival probability was 60.7 % in patients aged 65 years or under and 55.6 % in patients aged over 65 years (P = 0.40).

«We increased median survival time in animals by 40 %, which gives us enough evidence to go on to human clinical trials,» Belcher says.

We further found that in about 15 % of patients with FLT3 - ITD mutations, loss of the wt - FLT3 allele can be observed, and these patients have a particularly poor outcome, with a median disease free survival between 4 and 6 months.

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).